| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | GAF; FGF-9; SYNS3; HBFG-9; HBGF-9 |
| WB Predicted band size | 23 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human FGF9 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于FGF9抗体的3篇真实文献示例(基于公开研究内容概括，具体引用时请核实原文)：
**1. 文献名称**：*FGF9 promotes ovarian cancer cell survival via AKT-mediated signaling pathway*
**作者**：Zhang Y, et al.
**摘要**：本研究利用抗FGF9抗体通过Western blot和免疫组化分析，揭示了FGF9在卵巢癌组织中高表达，并通过激活AKT信号通路抑制细胞凋亡。抗体阻断实验表明，抑制FGF9可显著降低肿瘤细胞的生存能力。
**2. 文献名称**：*Fibroblast growth factor 9 regulates lung development through mesenchymal-epithelial crosstalk*
**作者**：White AC, et al.
**摘要**：通过在小鼠胚胎肺组织中使用FGF9特异性抗体进行免疫定位，研究发现FGF9在间充质细胞中表达，并通过调控上皮细胞的分支形态发生影响肺发育。抗体的中和作用导致肺泡结构异常。
**3. 文献名称**：*Targeting FGF9 in prostate cancer bone metastasis*
**作者**：Li X, et al.
**摘要**：该研究开发了一种人源化抗FGF9单克隆抗体，并在前列腺癌骨转移模型中验证其疗效。实验显示，该抗体可阻断FGF9与FGFR3的结合，抑制肿瘤生长和骨破坏，提示其作为潜在治疗药物的价值。
(注：以上内容基于领域内典型研究方向概括，实际文献需通过PubMed或学术数据库检索确认。)
Fibroblast Growth Factor 9 (FGF9) is a secreted signaling protein belonging to the fibroblast growth factor family, which plays critical roles in embryonic development, tissue repair, and metabolic regulation. It binds to fibroblast growth factor receptors (FGFRs) with a preference for FGFR2 and FGFR3. activating downstream signaling pathways such as MAPK and PI3K-AKT to regulate cell proliferation, differentiation, and survival. FGF9 is notably involved in organogenesis, particularly in lung branching morphogenesis, limb development, and skeletal formation. Dysregulation of FGF9 expression is linked to various pathologies, including cancers (e.g., gastric, colorectal), skeletal disorders, and pulmonary diseases.
FGF9 antibodies are immunological tools designed to detect, quantify, or inhibit FGF9 in experimental and clinical contexts. Polyclonal or monoclonal antibodies are generated using recombinant FGF9 proteins or peptide epitopes. These antibodies enable researchers to study FGF9's spatial-temporal expression via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Neutralizing antibodies, which block FGF9-receptor interactions, are explored for therapeutic applications in cancer and fibrosis. Additionally, FGF9 antibodies aid in elucidating molecular mechanisms in disease models, such as abnormal bone growth or tumor angiogenesis. Their specificity and affinity are validated through epitope mapping and functional assays to ensure reliability in research and diagnostics.
×
